OncoMatch/Clinical Trials/NCT07266493

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Is NCT07266493 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chemotherapy （Albumin bound paclitaxel and Carboplatin） for esophageal squamous cell carcinoma.

Phase 2RecruitingShanghai Zhongshan HospitalNCT07266493Data as of May 2026

Treatment: Chemotherapy （Albumin bound paclitaxel and Carboplatin） — This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: immunotherapy

Cannot have received: chemotherapy

Cannot have received: targeted therapy

Cannot have received: radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify